



Review

Arrhythmia management after device removal

Nobuhiro Nishii, MD*

Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan

ARTICLE INFO

Article history:

Received 3 July 2015

Received in revised form

31 August 2015

Accepted 14 September 2015

Available online 24 October 2015

Keywords:

Infection

Temporary pacing

Wearable cardioverter defibrillator

ABSTRACT

Arrhythmic management is needed after removal of cardiac implantable electronic devices (CIEDs). Patients completely dependent on CIEDs need temporary device back-up until new CIEDs are implanted. Various methods are available for device back-up, and the appropriate management varies among patients. The duration from CIED removal to implantation of a new CIED also differs among patients. Temporary pacing is needed for patients with bradycardia, a wearable cardioverter defibrillator (WCD) or catheter ablation is needed for patients with tachyarrhythmia, and sequential pacing is needed for patients dependent on cardiac resynchronization therapy. The present review focuses on arrhythmic management after CIED removal.

© 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Contents

| | |
|---|-----|
| 1. Introduction | 287 |
| 2. Before lead extraction | 287 |
| 3. Patients completely dependent on pacing | 287 |
| 4. Patients with high risk of tachyarrhythmia | 288 |
| 5. Patients dependent on CRT | 291 |
| 6. Summary | 292 |
| Conflict of interest | 292 |
| References | 292 |

1. Introduction

Cardiac implantable electronic devices (CIEDs) have become increasingly important in cardiac disease management worldwide. In fact, pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) have been used and developed since the 1960s. With the increase in the number of patients with CIEDs, the number of the CIED-related complications, including infection, has also been increasing. From 1996 to 2003, the rates of hospitalization for CIED infection reportedly increased faster than the rates of CIED implantation [1]. In patients with CIED infection, complete removal of all hardware, regardless of location (subcutaneous, transvenous, or epicardial), is the recommended treatment [2]. Various tools (traction devices, mechanical sheaths, laser sheaths, electrosurgical sheaths, rotating threaded tip sheath,

and telescoping sheaths) and methods (femoral approach, internal jugular approach, and a hybrid method with both, transvenous and surgical methods) have been developed for lead removal, and favorable results have been reported [3,4]. However, data to determine the optimal duration of antimicrobial therapy for CIED infection are limited. Further, data on appropriate management after CIED removal are also not available, although management of arrhythmic support after CIED removal is needed until a new CIED is implanted. In the present review, we focus on arrhythmic management from CIED removal to implantation of a new CIED.

2. Before lead extraction

Before a CIED can be removed, the consequences of removal need to be ascertained. Patients' dependence on pacemakers, the risk of tachyarrhythmia, and requirement of CRT must be determined, and the strategy for antiarrhythmic management should be determined on the basis of these investigations.

* Tel.: +81 86 235 7351; fax: +81 86 235 7353.

E-mail addresses: nnishii@md.okayama-u.ac.jp, nnnnishii2001@yahoo.co.jp

3. Patients completely dependent on pacing

CIED removal is associated with some problems. Therefore, whether the patient definitely needs a new CIED needs to be determined first. Second, until the new CIED is implanted, temporary pacing should be set up, especially in patients completely dependent on a pacemaker, using tools such as passive fixation leads, active fixation leads, and epicardial leads.

In their prospective, controlled study, Braun et al. [5] reported that transvenous pacing with active fixation is safe and is associated with a significantly lower rate of pacing-related adverse events than the standard technique of transvenous pacing using a passive external pacing catheter. Forty-nine patients with systemic infection and hemodynamic-relevant bradyarrhythmia were temporarily paced using either a conventional pacing wire/catheter ($n=26$, reference group) or a permanent bipolar active pacing lead, which was placed transcutaneously in the right ventricle and connected to an external pacing generator ($n=23$, external lead group). The sensing values in the two groups were almost identical, but the median pacing threshold was significantly higher in the reference group (1.0 V vs. 0.6 V, $P < 0.05$). Within comparable durations of pacing (median: 8.2 vs. 7.7 days), there were 24 pacing-related adverse events (including dislocation, resuscitation due to severe bradycardia, and local infection) in the reference group but only one in the external lead group ($P < 0.01$). None of these complications resulted in cardiac death. The reference group showed very high complication rates, mainly lead dislocation. Active fixation of temporary leads was only introduced in Japan in 2013. Moreover, a 2-week gap is generally observed between CIED removal and new CIED implantation in patients with pocket infection and a 4–6-week gap in patients with systemic infection. Patients with passively fixed temporary leads have a high risk of complications. Therefore, especially in patients completely dependent on pacing, permanent active fixation of leads permitting bipolar stimulation has been used for temporary pacing (Fig. 1). Recently, temporary active fixation of leads became available in Japan (Fig. 2) (TUA, OSYPKA AG, Germany).

Epicardial leads are feasible for cases in which open chest surgery is required. These leads carry a very low risk of percutaneous infection and lead dysfunction for a couple of weeks.

No clinical trial data are available for determining the optimal duration of antimicrobial therapy for CIED infection. However, therapy for 10–14 days after device removal is considered reasonable when CIED infection is limited to the pocket site, while at least 2–4 weeks of parenteral therapy after extraction of the infected device is recommended for patients with bloodstream infection [6].

Only one study has reported simultaneous contralateral (side-to-side) replacement of an infected CIED [7]. A one-stage exchange was performed in 68 consecutive patients over a 14-year period by a single cardiologist, and dual-chamber devices were used in two-thirds of these patients. Clinical presentations included device erosion (41%), cellulitis or abscess (35%), and endocarditis (24%). Fifty-nine patients (87%) were followed up for more than 1 year, and 9 patients were lost to follow-up at 1–10 months after the one-stage contralateral device exchange, with no newly identified CIED infections. Additional experience with one-stage contralateral device exchange is needed before it can be recommended for routine use.

The duration between CIED removal and re-implantation may vary among cases. We encountered two cases of early re-implantation. In the first case, the patient had CIED infection on both sides, and open chest surgery was needed to remove all CIEDs. An epicardial system was simultaneously implanted when the CIEDs were removed (Fig. 3). No re-infection was noted in the 2-year follow-up period. In the other case, early re-implantation




Fig. 1. Temporary pacing using a permanent active fixation lead. A permanent active fixation pacemaker lead was implanted. The electrode was connected to a generator.




Fig. 2. Temporary active fixation lead.

was performed because the patient experienced dementia and restlessness 3 days after CIED removal. In this case as well, no re-infection was noted in the 2-year follow-up period.

4. Patients with high risk of tachyarrhythmia

Patients with high-energy CIEDs are more likely to develop an infection than patients with a pacemaker [6]. Patients with a high risk of tachyarrhythmia should be temporarily managed using tools such as wearable cardioverter defibrillators (WCDs) and catheter ablation.

Healy et al. [8] reported on the cost effectiveness of using WCDs (Fig. 4) during the waiting period after infected CIED removal. The

Download English Version:

<https://daneshyari.com/en/article/2957484>

Download Persian Version:

<https://daneshyari.com/article/2957484>

[Daneshyari.com](https://daneshyari.com)